Story

AC Immune Stock Gains on FDA Fast Track for Parkinson's Therapy

ENTHMSVIIDZHZH-TWJAKOHI
Aug 11, 20262 min read
AC Immune Stock Gains on FDA Fast Track for Parkinson's Therapy
Text size
Background

AC Immune (NASDAQ: ACIU) shares gained in pre-market trading after the company announced a significant regulatory milestone for its Parkinson's disease treatment candidate. The U.S. Food and Drug Administration (FDA) granted Fast Track designation to ACI-7104 and simultaneously cleared its Investigational New Drug (IND) application.

FDA Accelerates Development Path

The dual decisions from the FDA mark a key step forward for AC Immune's anti-alpha-synuclein immunotherapy, which targets early-stage Parkinson's disease. The Fast Track designation is intended to facilitate the development and expedite the review of drugs to treat serious conditions and fill an unmet medical need.

Critically, the IND clearance allows the company to expand its ongoing Phase 2 VacSYn clinical trial to include U.S. clinical sites for the first time. According to the source, the FDA's decision was supported by positive interim data from the first part of the trial.

Supporting Data and Investor Outlook

The regulatory green light was based on a 76-week interim analysis of the VacSYn trial, which demonstrated a favorable safety profile with no clinically relevant safety concerns identified. This positive clinical signal has boosted investor confidence in the program's trajectory.

Sample IUX Markets – In-articleAd

Investors are also looking ahead to a future catalyst, with the full 104-week data from Part 1 of the study expected in the second half of 2026. The company is also keeping its broader neurodegeneration pipeline in focus with three studies being presented at the Alzheimer’s Association International Conference.

Market Reaction

The company-specific news was the clear driver of the stock's movement. Shares in AC Immune rose 3.4% in pre-open trading, reaching a high of $2.37 from a previous close of $2.28.

This gain stood in contrast to the broader market, which saw only mild gains in pre-market activity, indicating the move was attributable to the positive clinical and regulatory developments rather than wider market momentum.

Read next

More on Stocks
Back to latest news

LATEST